Number of Shares and Voting Rights of Innate Pharma as of August 1, 2025
Pursuant to the article L. 233-8 II of the French 'Code de Commerce' and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or ' AMF ') General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (' Innate ' or the ' Company ') releases its total number of shares outstanding as well as its voting rights as of August 1, 2025:
(1) The total number of theoretical voting rights (or 'gross' voting rights) is used as the basis for calculating the crossing of shareholding thresholds. In accordance with Article 223-11 of the AMF General Regulation, this number is calculated on the basis of all shares to which voting rights are attached, including shares whose voting rights have been suspended. The total number of theoretical voting rights includes voting rights attached to AGAP 2016, i.e. 130 voting rights for the AGAP 2016-1 and 111 voting rights for the AGAP 2016-2. No voting rights attached to AGAP 2017.
(2) The total number of exercisable voting rights (or 'net' voting rights) is calculated without taking into account the shares held in treasury by the Company, with suspended voting rights. It is released so as to ensure that the market is adequately informed, in accordance with the recommendation made by the AMF on July 17, 2007.
About Innate Pharma
Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to harness the innate immune system through three therapeutic approaches: multi-specific NK Cell Engagers via its ANKET ® (A ntibody-based NK cell E ngager T herapeutics) proprietary platform and Antibody Drug Conjugates (ADC) and monoclonal antibodies (mAbs).
Innate's portfolio includes several ANKET ® drug candidates to address multiple tumor types as well as IPH4502, a differentiated ADC in development in solid tumors. In addition, anti-KIR3DL2 mAb lacutamab is developed in advanced form of cutaneous T cell lymphomas and peripheral T cell lymphomas, and anti-NKG2A mAb monalizumab is developed with AstraZeneca in non-small cell lung cancer.
Innate Pharma is a trusted partner to biopharmaceutical companies such as Sanofi and AstraZeneca, as well as leading research institutions, to accelerate innovation, research and development for the benefit of patients.
Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.
Learn more about Innate Pharma at www.innate-pharma.com and follow us on LinkedIn and X.
Information about Innate Pharma shares
Disclaimer on forward-looking information and risk factors
This press release contains certain forward-looking statements, including those within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. The use of certain words, including 'anticipate,' 'believe,' 'can,' 'could,' 'estimate,' 'expect,' 'may,' 'might,' 'potential,' 'intend,' 'should,' 'will,' or the negative of these and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company's reliance on third parties to manufacture its product candidates, the Company's commercialization efforts and the Company's continued ability to raise capital to fund its development. For an additional discussion of risks and uncertainties, which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ('Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority ('AMF'), which is available on the AMF website http://www.amf-france.org or on Innate Pharma's website, and public filings and reports filed with the U.S. Securities and Exchange Commission ('SEC'), including the Company's Annual Report on Form 20-F for the year ended December 31, 2024, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public by the Company. References to the Company's website and the AMF website are included for information only and the content contained therein, or that can be accessed through them, are not incorporated by reference into, and do not constitute a part of, this press release.
In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by the Company or any other person that the Company will achieve its objectives and plans in any specified time frame or at all. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
15 minutes ago
- Yahoo
UBS Reiterates Buy on AppLovin (APP) With $540 PT After Q2 Beat
AppLovin Corporation (NASDAQ:APP) is one of the . On August 7, UBS analyst John Hodulik reiterated a Buy rating on the stock with a $540.00 price target. The rating affirmation follows Applovin's second quarter results, beating Wall Street's targets and guiding higher for sales in the current period. The firm increased its fiscal year 2026 EBITDA estimate to $6.18 billion, above the Street consensus of $5.65 billion. This was driven by better-than-expected gaming-related trends in the second and third quarters. The firm is optimistic that AppLovin's staggered rollout of its self-serve web-based ad platform, which begins in October, reduces medium-term risk for web-based advertising revenue growth. The rollout will start with referral-based advertisers before moving to general availability in the first half of 2026. An experienced financial analyst working with a laptop, illustrating the level of financial expertise. This will allow the company to deliver multi-quarter revenue growth particularly with expansion into international markets. Once the ad platform becomes generally available, advertisers will likely spend faster. The stock dip after-hours is therefore a buying opportunity: 'From here we see scope for GA advertisers to ramp spend faster as they benefit from more iteration on the platform. All-in, we'd take advantage of the AH weakness and reiterate our Buy rating on the basis of attractive risk/reward (2.1x), attractive valuation (37x FY26 P/E vs 42% 3-YR EPS CAGR) and improving catalyst path visibility.' AppLovin Corporation (NASDAQ:APP) provides a leading marketing platform powered by AI technology. While we acknowledge the potential of APP as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
35 minutes ago
- Yahoo
Why Rigetti Computing Stock Soared 9.3% This Week
Key Points A potential breakthrough from researchers at USC sent Rigetti stock higher. A new particle could help quantum companies solve quantum's error issue. The technology could still be many years away. 10 stocks we like better than Rigetti Computing › Shares of Rigetti Computing (NASDAQ: RGTI) jumped this week. The quantum computing start-up's stock rose 9.3% from last Friday's close. The move came as the S&P 500 and the Nasdaq-100 rose 2.4% and 3.7%, respectively. Rigetti and other quantum stocks were lifted this week by news that researchers at the University of Southern California may have found a way around obstacles the technology faces in its development. A "rescued" particle could boost quantum Researchers at the University of Southern California said that they had identified a new type of particle they call "neglectons," which could help solve one of quantum computing's biggest issues. The particles earned their name from their once-overlooked status; researchers had previously dismissed them as "mathematical garbage." Quantum computing faces a number of hurdles in its ongoing development. Chief among them is the inherent difficulty in error correction. These systems are fragile and hard to keep from degrading. The new particles could help scientists solve this issue through an approach called "braiding." Investors should remain cautious While the news is positive, it by no means indicates the issue is solved -- or is close to being solved. This is a highly experimental field at the very edge of human knowledge and theory, let alone practical engineering. I think many investors are getting ahead of themselves, and it could be many years, if not decades, before we see viable quantum computing at scale. Rigetti is one of the more promising quantum companies, but at its current valuation, I would not invest. Do the experts think Rigetti Computing is a buy right now? The Motley Fool's expert analyst team, drawing on years of investing experience and deep analysis of thousands of stocks, leverages our proprietary Moneyball AI investing database to uncover top opportunities. They've just revealed their to buy now — did Rigetti Computing make the list? When our Stock Advisor analyst team has a stock recommendation, it can pay to listen. After all, Stock Advisor's total average return is up 1,047% vs. just 181% for the S&P — that is beating the market by 865.68%!* Imagine if you were a Stock Advisor member when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,563!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,108,033!* The 10 stocks that made the cut could produce monster returns in the coming years. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025 Johnny Rice has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Why Rigetti Computing Stock Soared 9.3% This Week was originally published by The Motley Fool
Yahoo
2 hours ago
- Yahoo
Why Clean Energy Fuels Stock Raced Nearly 13% Higher Today
Key Points The energy company delivered better-than-expected numbers in its latest earnings release. It beat on both the top and bottom lines with second-quarter results. 10 stocks we like better than Clean Energy Fuels › Clean Energy Fuels (NASDAQ: CLNE), a company that sells renewable natural gas (RNG) as a fuel for automobiles, scored a clean win on the stock exchange Friday. Its shares zoomed almost 13% higher after it unveiled its latest set of quarterly results, which, among other things, featured a double beat on analyst estimates. With that performance, it crushed the 0.8% increase of the S&P 500 index. Confidence renewed after results published Clean Energy Fuels' second quarter saw the company post revenue of $102.6 million, which was nearly 5% higher on a year-over-year basis. Non-GAAP (adjusted) net income fell to $337,000, shaking out to less than $0.01 per share. Image source: Getty Images. Despite the bottom-line decline, analysts were expecting notably worse results. On average, they were modeling slightly over $94 million for revenue and a net loss of $0.06 per share. In its earnings release, Clean Energy Fuels CEO Andrew Littlefair said, "RNG remains the most immediate and cost-effective clean transportation fuel, as we see continued strong demand reflected in our solid second quarter results." Littlefair also pointed out that the government's recently passed "big, beautiful bill" supports the RNG market. Its extension of the clean fuel production tax credit should be a boon for RNG producers and suppliers. Powering big fleets Clean Energy Fuels is doing quite well in its rather limited niche, and during the quarter, it executed new supply arrangements with a number of municipal transit fleets, including LA Metro in Los Angeles. Such customers tend to be long-term and reliable, so it'll be worthwhile for investors to keep an eye on how the segment continues to develop for the company. Should you invest $1,000 in Clean Energy Fuels right now? Before you buy stock in Clean Energy Fuels, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Clean Energy Fuels wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,427!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,119,863!* Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Why Clean Energy Fuels Stock Raced Nearly 13% Higher Today was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
